Related Experiment Video

Updated: Dec 10, 2025

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

655

Management of Helicobacter pylori

Erick A Argueta1, Steven F Moss

  • 1Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Current Opinion in Gastroenterology
|September 2, 2020
PubMed

Insights

Effective Helicobacter pylori treatment is crucial for preventing gastric cancer. Current challenges include antibiotic resistance and suboptimal management pathways, necessitating improved testing and treatment strategies.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Oncology

Background:

  • Helicobacter pylori (H. pylori) management is a daily concern for clinicians globally.
  • Growing evidence links H. pylori eradication to reduced gastric cancer risk.
  • Debate and research continue regarding optimal H. pylori treatment and management strategies.

Purpose of the Study:

  • To review current clinical evidence on H. pylori management.
  • To identify challenges and suggest improvements in H. pylori treatment pathways.
  • To highlight the importance of H. pylori eradication for gastric health.

Main Methods:

  • Systematic literature search on PubMed using terms 'pylori and treatment' and 'pylori and management'.
  • Selection of over 1000 relevant articles published between January 1, 2019, and April 30, 2020.
  • Focus on clinically relevant articles for review.

Main Results:

  • High rates of resistance to clarithromycin and levofloxacin are linked to treatment failures.
  • Alternative treatment regimens and susceptibility testing are increasingly important.
  • Suboptimal implementation of H. pylori testing and treatment pathways persists.

Conclusions:

  • Improved measurement of H. pylori-related clinical outcomes is needed.
  • Identifying and addressing implementation gaps can optimize H. pylori management.
  • Enhanced strategies are required to leverage H. pylori knowledge for disease prevention.
Abstract

More Related Videos

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.1K
Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis04:56

Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis

Published on: May 16, 2025

915

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
840
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
301
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
940
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
676
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
709
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
778